<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04500496</url>
  </required_header>
  <id_info>
    <org_study_id>aswu/351/4/19</org_study_id>
    <nct_id>NCT04500496</nct_id>
  </id_info>
  <brief_title>Vaginal Dinoprostone Versus Isonicotinic Acid Hydrazide Prior to Diagnostic Office Hysteroscopy</brief_title>
  <official_title>Vaginal Dinoprostone Versus Vaginal Isonicotinic Acid Hydrazide Prior to Diagnostic Office Hysteroscopy in Postmenopausal Patients: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aswan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aswan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effectiveness of vaginal dinoprostone and vaginal Isonicotinic acid hydrazide&#xD;
      in minimizing the pain experienced by postmenopausal patients during diagnostic ofﬁce&#xD;
      hysteroscopy and to assess the ease of insertion of hysteroscope as reported by the&#xD;
      hysteroscopist.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      hysteroscopy is commonly used in the diagnosis and treatment of intrauterine lesions such as&#xD;
      polyps, ﬁbroids, septa, and adhesions, and in the presence of abnormal bleeding and during&#xD;
      the removal of an intrauterine device or foreign body. Cervical ripening is made possible by&#xD;
      the use of medication through different routes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">January 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>open label randomized controlled study</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>open label randomized controlled study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Intensity of pain</measure>
    <time_frame>10 minutes</time_frame>
    <description>Pain intensity will be assessed by visual analogue scale during the procedure. Visual analogue scale ranging from 0 to 10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Operative time</measure>
    <time_frame>15 minutes</time_frame>
    <description>From the introduction of hysteroscope into the vagina till compilation of hysteroscopic examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain intensity will be assessed by visual analogue scale</measure>
    <time_frame>30 minutes after the procedure</time_frame>
    <description>Pain intensity will be assessed by visual analogue scale 30 minutes after the procedure. Visual analogue scale ranging from 0 to 10</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Postmenopausal Bleeding</condition>
  <arm_group>
    <arm_group_label>INH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 tablet of INH 900 mg inserted by the patient 12 hours before the scheduled office hysteroscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dinoprostone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia &amp; Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INH</intervention_name>
    <description>3 tablet of INH inserted by the patient 12 hours before the scheduled office hysteroscopy</description>
    <arm_group_label>INH</arm_group_label>
    <other_name>Isonicotinic acid hydrazide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dinoprostone</intervention_name>
    <description>1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia &amp; Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.</description>
    <arm_group_label>dinoprostone</arm_group_label>
    <other_name>prostin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Menopausal patients with an indication for ofﬁce hysteroscopy (postmenopausal bleeding&#xD;
             or abnormal ultrasound ﬁndings)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Nulliparous patients&#xD;
&#xD;
          -  patients with cervical pathology&#xD;
&#xD;
          -  retroverted uterus (detected by transvaginal ultrasound)&#xD;
&#xD;
          -  previous cervical surgery&#xD;
&#xD;
          -  patients with severe vaginal bleeding&#xD;
&#xD;
          -  allergy or contraindications to dinoprostone or INH therapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Menopausal patients with an indication for ofﬁce hysteroscopy</gender_description>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>nahla w Shady, md</last_name>
    <role>Study Chair</role>
    <affiliation>Aswan universirty</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>hany f Sallam, md</last_name>
    <phone>+20102435461</phone>
    <phone_ext>002</phone_ext>
    <email>hany.farouk@aswu.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>nahla w Shady, md</last_name>
    <phone>+201022336052</phone>
    <phone_ext>002</phone_ext>
    <email>hanygyne@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aswan University Hospital</name>
      <address>
        <city>Aswan</city>
        <zip>81528</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hany F Sallam, MD</last_name>
      <phone>0122336052</phone>
      <phone_ext>002</phone_ext>
      <email>hany.farouk@aswu.edu.eg</email>
    </contact>
    <contact_backup>
      <last_name>Nahla W Shady, MD</last_name>
      <phone>01092440504</phone>
      <phone_ext>002</phone_ext>
      <email>nahla.elsayed@aswu.edu.eg</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 3, 2020</study_first_submitted>
  <study_first_submitted_qc>August 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2020</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aswan University Hospital</investigator_affiliation>
    <investigator_full_name>hany farouk</investigator_full_name>
    <investigator_title>A Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Dinoprostone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

